April 29, 2020 / 6:13 AM / in a month

BRIEF-Richter, Mycenax sign asset purchase agreement on biosimilar drug

April 29 (Reuters) - Hungary’s Richter says in statement on Budapest Stock Exchange web site:

* ENTERED INTO AN ASSET PURCHASE AGREEMENT WITH TAIWANESE BIOTECH COMPANY MYCENAX FOR THE BIOSIMILAR TOCILIZUMAB

* RICHTER RECEIVES WORLDWIDE RIGHTS TO DEVELOP, MANUFACTURE AND COMMERCIALISE THE PRODUCT

* RICHTER TO PAY MYCENAX $16.5 MILLION IN FOUR INSTALLMENTS Source text for Eikon: bit.ly/2VKjInq Further company coverage: (Reporting by Marton Dunai)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below